Guanfacine: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AWMSG (Wales), CIPM (Spain) and SMC (Scotland), among others, recommended or restricted guanfacine, while ZIN (Netherlands) did not recommend it.
Assessment has run over 10.4 years, from 7 Feb 2016 at SMC (Scotland) to 16 Jul 2026 at AOTMIT (Poland).
AOTMIT (Poland) changed its position: not recommended on 30 Nov 2020, restricted by 16 Jul 2026, after a resubmission.
No assessment is on file from HAS (France), PHARMAC (New Zealand) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 4 of 11 records date from 2023 or later.
3 distinct indication wordings are recorded for guanfacine by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 11 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess guanfacine, on 7 Feb 2016; CIPM (Spain) did not open a file until 19 Jun 2025 — an unusually long tail of 9.3 years between the earliest and latest system to look at it.
2 of the 7 agencies here assessed guanfacine more than once, AOTMIT (Poland) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for guanfacine.
The full ledger for guanfacine reads 5 not recommended, 4 recommended and 2 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 25 Jul 2025 | Intuniv reimbursement recommendation | not recommended | source |
| CIPM (Spain) | 19 Jun 2025 | Indicación terapéutica autorizada: Paxneury está indicado para el tratamiento del trastorno por déficit de atención e hi… | financed by the SNS · art. 92 a, c | source |
| AWMSG (Wales) | 29 May 2025 | Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stim… | recommended (limited) | source |
| PBAC (Australia) | 2018 | Attention deficit hyperactivity disorder (ADHD) | The PBAC recommended the Authority Required (STREAMLINED) listing of guanfacine, as add-on… | source |
| ZIN (Netherlands) | 18 Jul 2016 | GVS-advies guanfacine (Intuniv®) bij ADHD | not reimbursed (GVS) | source |
6 further decisions for guanfacine, across 4 agencies, are not shown here. They include the most recent record on file, 16 Jul 2026 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- atomoxetine — divergent outcome (not recommended vs recommended) on a shared indication
- lisdexamfetamine — divergent outcome (not recommended vs recommended) on a shared indication
- methylphenidate — divergent outcome (not recommended vs recommended) on a shared indication
- mosunetuzumab — also decided by AOTMIT in 2026Q3
- ganaxolone — also decided by AOTMIT in 2026Q3
- delgocitinib — also decided by AOTMIT in 2026Q3
Coverage: 11 decisions for guanfacine from 7 agencies, 2016 to 2026. Data to 7 Sep 2026. ATC class C02A — Antihypertensives. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.